Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nurix Therapeutics ( (NRIX) ) has shared an announcement.
On January 12, 2026, Nurix Therapeutics presented its 2025 performance and 2026 goals at the 44th Annual J.P. Morgan Healthcare Conference, highlighting 2025 as a breakthrough year marked by significant clinical, partnering, and financing milestones. The company reported strong clinical progress for its lead BTK degrader bexobrutideg, including initiation of the pivotal DAYBreak-201 Phase 2 trial in relapsed or refractory chronic lymphocytic leukemia designed to support accelerated approval, alongside previously disclosed data from ASH showing an 83% overall response rate and median progression-free survival of 22.1 months. Nurix also advanced partnered programs, with an IRAK4 degrader in an ongoing Phase 1 study with Gilead, a STAT6 degrader moving into IND-enabling studies with Sanofi, and healthy volunteer studies starting for a new bexobrutideg formulation for inflammatory and immunology indications. Financially, the company strengthened its balance sheet through a $250 million follow-on offering and $47 million in non-dilutive capital from discovery partnerships, ending with pro forma cash and investments of roughly $663.8 million as of late 2025, positioning it to support continued pipeline development and reinforcing its standing in the targeted protein degradation field.
The most recent analyst rating on (NRIX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.
Spark’s Take on NRIX Stock
According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.
Nurix Therapeutics’ overall stock score is driven by its strong technical momentum and positive corporate developments. However, financial challenges and valuation concerns weigh on the score, reflecting the company’s current profitability and cash flow issues.
To see Spark’s full report on NRIX stock, click here.
More about Nurix Therapeutics
Nurix Therapeutics is a biotechnology company focused on developing degrader-based medicines that harness targeted protein degradation to treat cancer and autoimmune and inflammatory diseases. Its pipeline includes proprietary and partnered programs such as BTK degraders bexobrutideg (NX-5948) and BTK-IKZF degrader zelebrudomide (NX-2127), the CBL-B modulator NX-1607 for immuno-oncology, and multiple degrader and degrader antibody conjugate candidates being advanced with partners including Gilead and Sanofi across oncology and inflammation & immunology indications.
Average Trading Volume: 1,796,707
Technical Sentiment Signal: Buy
Current Market Cap: $1.89B
Find detailed analytics on NRIX stock on TipRanks’ Stock Analysis page.